Page 65 - 南京医科大学学报自然科学版
P. 65

第43卷第5期         陆嘉宁,马 佩,高 雯,等. 75岁以上癌症患者免疫治疗相关不良反应的回顾性分析[J].
                  2023年5月                     南京医科大学学报(自然科学版),2023,43(5):640-647                        ·647 ·


               [38] GANDHI L,RODRIGUEZ⁃ABREU D,GADGEEL S,et            can society of clinical oncology clinical practice guideline
                    al. Pembrolizumab plus chemotherapy in metastatic non⁃  [J]. J Clin Oncol,2018,36(17):1714-1768
                    small⁃cell lung cancer[J]. N Engl J Med,2018,378(22):  [42] NOSAKI K,SAKA H,HOSOMI Y,et al. Safety and effica⁃
                    2078-2092                                          cy of pembrolizumab monotherapy in elderly patients with
               [39] PAZ⁃ARES L,LUFT A,VICENTE D,et al. Pembrolizum⁃    PD ⁃ L1 ⁃ positive advanced non ⁃ small ⁃ cell lung cancer:
                    ab plus chemotherapy for squamous non⁃small⁃cell lung  Pooled analysis from the KEYNOTE ⁃ 010,KEYNOTE ⁃
                    cancer[J]. N Engl J Med,2018,379(21):2040-2051     024,and KEYNOTE⁃042 studies[J]. Lung Cancer,2019,
               [40] SOCINSKI M A,JOTTE R M,CAPPUZZO F,et al.           135:188-195
                    Atezolizumab for first ⁃ line treatment of metastatic non⁃  [43] SATTAR J,KARTOLO A,HOPMAN W M,et al. The effi⁃
                    squamous NSCLC[J]. N Engl J Med,2018,378(24):      cacy and toxicity of immune checkpoint inhibitors in a re⁃
                    2288-2301                                          al ⁃ world older patient population[J]. J Geriatr Oncol,
               [41] BRAHMER J R,LACCHETTI C,SCHNEIDER B J,et al.       2019,10(3):411-414
                    Management of immune⁃related adverse events in patients                 [收稿日期] 2023-01-30
                    treated with immune checkpoint inhibitor therapy:Ameri⁃                     (本文编辑:唐      震)





                





               (上接第603页)                                               prognosis of patients with liver cancer[J]. Oncoimmunolo⁃
                    PD⁃L1 表达的影响[J].南京医科大学学报(自然科学                       gy,2017,6(1):e1264562
                    版),2021,41(4):503-508                        [68] LI F,WEI H,WEI H,et al. Blocking the natural killer
               [65] GE Z,ZHOU G,CAMPOS CARRASCOSA L,et al. TIGIT       cell inhibitory receptor NKG2A increases activity of hu⁃
                    and PD1 co⁃blockade restores ex vivo functions of human  man natural killer cells and clears hepatitis B virus infec⁃
                    tumor⁃infiltrating CD8(+)T cells in hepatocellular carci⁃  tion in mice[J]. Gastroenterology,2013,144(2):392-
                    noma[J]. Cell Mol Gastroenterol Hepatol,2021,12(2):  401
                    443-464                                      [69] BATTIN C,KAUFMANN G,LEITNER J,et al. NKG2A⁃
               [66] MCGRANAHAN N,ROSENTHAL R,HILEY C T,et al.          checkpoint inhibition and its blockade critically depends
                    Allele⁃specific HLA loss and immune escape in lung can⁃  on peptides presented by its ligand HLA⁃E[J]. Immunolo⁃
                    cer evolution[J]. Cell,2017,171(6):1259-1271       gy,2022,166(4):507-521
               [67] SUN C,XU J,HUANG Q,et al. High NKG2A expression                         [收稿日期] 2023-02-11
                    contributes to NK cell exhaustion and predicts a poor                       (本文编辑:唐      震)
   60   61   62   63   64   65   66   67   68   69   70